Relationship between patient-reported health-related quality of life as measured with the SF-36 or SF-12 and their mortality risk in patients with diverse cancer type: a meta-analysis.
{"title":"Relationship between patient-reported health-related quality of life as measured with the SF-36 or SF-12 and their mortality risk in patients with diverse cancer type: a meta-analysis.","authors":"Takashi Tanaka, Shinichiro Morishita, Jiro Nakano, Junichiro Inoue, Taro Okayama, Katsuyoshi Suzuki, Keiichi Osaki, Takuya Fukushima","doi":"10.1007/s10147-024-02659-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This systematic review and meta-analysis aimed to investigate the association between health-related quality of life (HRQOL) as measured with the Short Form 36 Health Survey (SF-36) or Short Form 12 Health Survey (SF-12) and mortality risk in patients with diverse types of cancer.</p><p><strong>Methods: </strong>A literature search was conducted using CINAHL, PubMed/MEDLINE, and Scopus databases to collect articles published before December 2022. Of these, observational studies that examined the association between HRQOL and mortality risk in patients with various cancer types were extracted. A subgroup analysis with a focus on the timing when HRQOL assessment was performed.</p><p><strong>Results: </strong>Nineteen studies were included in the final analysis. Through overall analysis of the timing of HRQOL measurements, most domains were found to be significantly associated with the mortality risk, irrespective of the timing of assessment, but HRQOL assessed in pre-treatment and palliative phases had particularly strong association.</p><p><strong>Conclusions: </strong>In the present review, the physical functioning domain of HRQOL was found to be associated with mortality risk in a diverse group of cancer patients. This suggests the need for supportive care to improve HRQOL in cancer patients.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"252-266"},"PeriodicalIF":2.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-024-02659-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: This systematic review and meta-analysis aimed to investigate the association between health-related quality of life (HRQOL) as measured with the Short Form 36 Health Survey (SF-36) or Short Form 12 Health Survey (SF-12) and mortality risk in patients with diverse types of cancer.
Methods: A literature search was conducted using CINAHL, PubMed/MEDLINE, and Scopus databases to collect articles published before December 2022. Of these, observational studies that examined the association between HRQOL and mortality risk in patients with various cancer types were extracted. A subgroup analysis with a focus on the timing when HRQOL assessment was performed.
Results: Nineteen studies were included in the final analysis. Through overall analysis of the timing of HRQOL measurements, most domains were found to be significantly associated with the mortality risk, irrespective of the timing of assessment, but HRQOL assessed in pre-treatment and palliative phases had particularly strong association.
Conclusions: In the present review, the physical functioning domain of HRQOL was found to be associated with mortality risk in a diverse group of cancer patients. This suggests the need for supportive care to improve HRQOL in cancer patients.
期刊介绍:
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.